Exalenz Bioscience Acquired for $49M
Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
Golan Hazani | 13:44 19.02.2020
Tel Aviv-listed Exalenz Bioscience Ltd. announced Wednesday it has accepted a deal to be acquired by an unnamed U.S. company for NIS 6.1 (approximately $1.78) per share, or a total of NIS 169 million (approximately $49.9 million), confirming an earlier report by Calcalist. The deal reflects a 70% premium on Exalenz’s share price at the beginning of trade Wednesday. Exalenz first announced it was seeking a buyer in October. Back then, the company said it had hired the services of a leading investment bank to oversee its sale.